Aridis Pharmaceuticals Inc (ARDS)

[ProfitScout]

The ARDS approach of using monoclonal antibodies to counter serious infectious diseases appears to be one of the most promising strategies emerging in medicine today. I am also especially pleased to see that ARDS is currently applying this method to defending against the Covid-19 mutation variants as this remains the most serious threat from the pandemic and will likely continue for years to come.

From the company news:

*Announced the addition of a second inhaled monoclonal antibody ("mAb") to neutralize newly emerging COVID-19 mutated variant to form a cocktail of two mAbs. The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering. A clinical Phase 1/2 study is expected to be launched in 2H 2021.

More Info here: http://www.prnewswire.com/news-releases/aridis-pharmaceuticals-announces-first-quarter-2021-results-301289072.html